| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.aurolabs.com | |
| Market Cap | 116.36 Cr. | |
| Enterprise Value(EV) | 124.73 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 11.54 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 16.17 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 40.73 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 63.77 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 2.93 | Calculated using Price: 186.70 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.62 Cr. | 6,232,500 Shares |
| FaceValue | 10 | |
| About Auro Laboratories Ltd. | ||
| Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah. | ||
| 1 Day |
|
-0.05% |
| 1 Week |
|
+1.68% |
| 1 Month |
|
+25.38% |
| 3 Month |
|
+51.54% |
| 6 Month |
|
+57.72% |
| 1 Year |
|
+180.61% |
| 2 Year |
|
+73.40% |
| 5 Year |
|
+176.27% |
| 10 Year |
|
+3024.17% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 11.01 | 10.83 | 9.06 | 31.53 | 28.95 | 20.84 | 28.67 | 9.47 | 7.43 | |
| Return on Capital Employed (%) | 10.76 | 11.21 | 20.24 | 28.65 | 29.12 | 24.8 | 38.88 | 12.2 | 9.92 | |
| Return on Assets (%) | 2.89 | 3.24 | 3.11 | 12.34 | 13.78 | 12.32 | 19.34 | 5.87 | 4.4 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 8 | 9 | 9 | 13 | 17 | 22 | 29 | 32 | 34 | 37 | |
| Non Curr. Liab. | 8 | 7 | 11 | 8 | 6 | 5 | 4 | 3 | 4 | 11 | |
| Curr. Liab. | 14 | 10 | 6 | 10 | 10 | 6 | 9 | 20 | 18 | 14 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 29 | 26 | 27 | 30 | 33 | 32 | 42 | 55 | 56 | 62 | |
| Non Curr. Assets | 11 | 13 | 13 | 15 | 15 | 14 | 14 | 18 | 21 | 26 | |
| Curr. Assets | 18 | 12 | 14 | 16 | 19 | 18 | 28 | 37 | 35 | 36 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 29 | 26 | 27 | 30 | 33 | 32 | 42 | 55 | 56 | 62 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 33 | 28 | 35 | 41 | 47 | 44 | 54 | 51 | 53 | 55 | |
| Other Income | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Total Income | 33 | 28 | 36 | 41 | 48 | 45 | 55 | 52 | 54 | 57 | |
| Total Expenditure | -30 | -25 | -31 | -34 | -40 | -38 | -43 | -46 | -49 | -44 | |
| PBIDT | 3 | 3 | 5 | 7 | 8 | 7 | 12 | 6 | 5 | 12 | |
| Interest | -2 | -2 | -1 | -1 | -1 | -1 | 0 | -1 | -1 | -1 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -2 | -1 | -2 | -2 | -3 | -1 | -1 | -3 | |||
| Exceptional Items | |||||||||||
| PAT | 1 | 1 | 1 | 4 | 4 | 4 | 7 | 3 | 2 | 7 | |
| Adjusted EPS | 1 | 1 | 1 | 6 | 7 | 7 | 12 | 5 | 4 | 12 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 4 | -1 | 8 | 6 | 5 | 7 | 9 | 13 | -7 | 3 | |
| Cash Fr. Inv. | -1 | -1 | -2 | -2 | -2 | -3 | -2 | -4 | -5 | -5 | |
| Cash Fr. Finan. | -3 | 1 | -5 | -4 | -2 | -2 | -6 | 0 | 10 | -8 | |
| Net Change | 1 | -1 | 0 | 0 | 1 | 2 | 2 | 9 | -2 | -10 | |
| Cash & Cash Eqvt | 1 | 0 | 1 | 1 | 2 | 4 | 6 | 15 | 12 | 2 |
|
Wed, 17 Apr 2024
Reporting Of Violation Under SEBI (Prohibition Of Insider Trading) Regulations 2015 Please find attached report on violation of code of conduct (for insider trading) to regulate monitor and reporting of trading by Designated Person and their immediate relatives. |
|||||||||||||||||||||
|
Tue, 16 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Sweta Agarwal Designation: Company Secretary EmailId: cs@aurolabs.com Name of the Chief Financial Officer: Shaan Jain Designation: CFO EmailId: accountsmgr@aurolabs.com Date: 16/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Tue, 16 Apr 2024
COMPLIANCE CERTIFICATE UNDER REG 40(10) OF SEBI LODR REGULATIONS 2015 COMPLIANCE CERTIFICATE |
| Fri, 19 Apr 2024 |
Close Within 52 Week High Zone
|
High Increase in 1 Month
|
High Increase in 3 Months
|
High Increase in 6 Months
|
High Increase in 1 Year
|
